Adjuvant PD-1-based therapies for high-risk resected melanomas are here to stay

Am J Surg. 2024 Sep:235:115791. doi: 10.1016/j.amjsurg.2024.115791. Epub 2024 Jun 1.

Authors

Tarek Haykal¹, Carlo Contreras²

Affiliations

¹ Department of Internal Medicine, Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, OH, 43210, USA. Electronic address: tarek.haykal@osumc.edu.
² Department of Surgery, Division of Surgical Oncology, The Ohio State University College of Medicine, Columbus, OH, 43210, USA.

PMID: 38845270
DOI: 10.1016/j.amjsurg.2024.115791

No abstract available

Publication types

Editorial

MeSH terms

Chemotherapy, Adjuvant
Humans
Immune Checkpoint Inhibitors / therapeutic use
Melanoma* / drug therapy
Melanoma* / surgery
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Skin Neoplasms / pathology
Skin Neoplasms / surgery

Substances

Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor